The new facility will expand Brookwood’s capacity for R&D activities and clinical manufacturing in support of customer projects. Additionally, the building will be SurModics’s corporate center for commercial GMP manufacturing of drug delivery products for pharmaceutical and biotechnology customers.
The pre-existing facility, with both office and warehouse space, is located at 750 Lakeshore Parkway in Birmingham and is less than one-half mile from Brookwood’s current headquarters. Build-out to support a number of existing programs is planned immediately. Additional expansion, as dictated by business growth over the next several years, will allow for eventual consolidation of all of Brookwood’s operations into this facility. When completed, SurModics expects direct support from the state and local governments of several million dollars. In addition, the investments in the facility will qualify the company for other tax incentives.
Bruce Barclay, president and CEO of SurModics, said: “The facility expansion we are announcing today is designed to support this growing interest in both R&D and manufacturing services at Brookwood, and serves to highlight the strength of our business and the optimism we have in its future. In addition, we plan to manufacture the late-stage clinical trial and commercial I-vation TA Intravitreal Implant product for our customer Merck & Co. in this facility.”